By Cures Within Reach Clinical Trial for Ultrarare Hemophagocytic Lymphohistiocytosis Receives Funding to Repurpose Existing Blood Cancer Treatment
|
By Cures Within Reach Pitch Event on June 6 in Philadelphia Features 4 Clinical Repurposing Projects
|
 | By Keystone Symposia Keystone Symposia, in partnership with Vienna BioCenter Research Institutes GMI, IMBA, IMP and MFPL, is pleased to announce a series of scientific research conferences to be held at Vienna BioCenter in Vienna, Austria.
|
By Partners4Access Sophie Schmitz, Managing Partner of Partners4Access is to chair a panel discussion on rare diseases at the BioIndustry Association or BIA's event UK Bioscience Forum on October 18, 2018.
|
By SMi Group SMi Reports: With just 4 weeks to go until the 8th Annual Orphan Drugs & Rare Diseases Conference, places for the conference and accompanying workshop on 16th October are becoming limited.
|
By SMi SMi Reports: 8th Annual Orphan Drugs and Rare Diseases Conference to bring together pharmaceutical companies, non-profit organisations and orphan drug developers to explore alliances and facilitate progress.
|
By XpertDox XpertDox, a data analytics firm focused on improving healthcare outcomes for patients with serious and rare diseases, today announced that the University of Alabama at Birmingham (UAB), one of the largest academic medical centers in the United States,...
|
By SMi SMi Group reports: Exclusive interviews with Toni Mathieson - Niemann-Pick UK and Nicolas Sireau - AKU Society in the run up to the Orphan Drugs and Rare Diseases Conference taking place on the 17 - 18 October 2018 in London
|
By Partners4Access Free webinar will be held on Wednesday April 4 2018 at 17:00 GMT/1200 EST/9:00 PST.
|
By Partners4Access Partners4Access comment on the new Eurordis Position Paper on access to orphan drugs
|
By XpertDox LLC XpertDox has launched the new Clinical Trial finder search engine. This functionality will enable the patients to find all ongoing clinical trials for a particular disease.
|
By Partners4Access Partners4Access (P4A), the specialists in orphan drug access, are launching a weekly newsletter focussing on key developments in the rare diseases and orphan drugs market access landscape.
|
 | By SMi Group "...The U.S. FDA is on track to set a record for orphan drugs approved this year. At last count, 42 orphan drugs have been approved between January 1, 2017 and August 9, 2017.
|
| By SMi Group Rare disease expert speaks to SMI Group in the run-up to her featured address on the 100K Genome
|
